DrugDec 18, 2024
Levothyroxine Sodium Tablets USP, 175 mcg recall — FDA D-0121-2025
Superpotent Drug and Subpotent Drug: potency failures obtained
Class IIFDA: OngoingViatris Inc
December 2024 recalls — page 2
These records include useful source details for the selected month.
DrugDec 18, 2024
Levothyroxine Sodium Tablets USP, 112 mcg recall — FDA D-0128-2025
Superpotent Drug and Subpotent Drug: potency failures obtained
Class IIFDA: OngoingViatris Inc
DrugDec 18, 2024
Levothyroxine Sodium Tablets, USP, 137 mcg (0.137 mg), 100 Tablets per carton recall — FDA D-0134-2025
Subpotent and Superpotent Drug
Class IIFDA: OngoingMylan Institutional, Inc.
DrugDec 18, 2024
Levothyroxine Sodium Tablets USP, 200 mcg recall — FDA D-0122-2025
Superpotent Drug and Subpotent Drug: potency failures obtained
Class IIFDA: OngoingViatris Inc
DrugDec 18, 2024
Levothyroxine Sodium Tablets USP, 125 mcg recall — FDA D-0118-2025
Superpotent Drug and Subpotent Drug: potency failures obtained
Class IIFDA: OngoingViatris Inc
DrugDec 18, 2024
SEVERE COLD AND FLU PLUS CONGESTION Kirkland Severe Cold & Flu Plus Congestion: Day - 112 recall — FDA D-0115-2025
CGMP Deviations: Released product should have been rejected.
Class IIFDA: TerminatedLNK International, Inc.
DrugDec 18, 2024
Levothyroxine Sodium Tablets, USP, 112 mcg (0.112 mg), 100 Tablets per carton recall — FDA D-0132-2025
Subpotent and Superpotent Drug
Class IIFDA: OngoingMylan Institutional, Inc.
DrugDec 18, 2024
Levothyroxine Sodium Tablets, USP, 150 mcg (0.150 mg), 100 Tablets per carton recall — FDA D-0135-2025
Subpotent and Superpotent Drug
Class IIFDA: OngoingMylan Institutional, Inc.
DrugDec 18, 2024
Levothyroxine Sodium Tablets, USP, 100 mcg (0.1 mg), 100 Tablets per carton recall — FDA D-0131-2025
Subpotent and Superpotent Drug
Class IIFDA: OngoingMylan Institutional, Inc.
DrugDec 18, 2024
Levothyroxine Sodium Tablets USP, 50 mcg recall — FDA D-0124-2025
Superpotent Drug and Subpotent Drug: potency failures obtained
Class IIFDA: OngoingViatris Inc
DrugDec 18, 2024
Levothyroxine Sodium Tablets, USP, 175 mcg (0.175 mg), 100 Tablets per carton recall — FDA D-0136-2025
Subpotent and Superpotent Drug
Class IIFDA: OngoingMylan Institutional, Inc.
DrugDec 18, 2024
Levothyroxine Sodium Tablets, USP, 125 mcg (0.125 mg), 100 Tablets per carton recall — FDA D-0133-2025
Subpotent and Superpotent Drug
Class IIFDA: OngoingMylan Institutional, Inc.
DrugDec 18, 2024
Levothyroxine Sodium Tablets USP, 100 mcg recall — FDA D-0127-2025
Superpotent Drug and Subpotent Drug: potency failures obtained
Class IIFDA: OngoingViatris Inc
DrugDec 18, 2024
Levothyroxine Sodium Tablets USP, 150 mcg recall — FDA D-0120-2025
Superpotent Drug and Subpotent Drug: potency failures obtained
Class IIFDA: OngoingViatris Inc
VehicleDec 17, 2024
Tesla pressure monitoring and regulating systems recall — NHTSA campaign 24V935000
Tesla, Inc. (Tesla) is recalling certain 2024 Cybertruck, 2017-2025 Model 3, and 2020-2025 Model Y vehicles. The tire pressure monitoring system (TPMS) warning light may not remain…
pressure monitoring and regulating systemsTesla, Inc.
DrugDec 11, 2024
Midlab MAXIM Assure Antibacterial, Chloroxylenol 0.1%, Net Contents: One U.S recall — FDA D-0087-2025
cGMP Deviations: Out of specification results for micro in hand soap products.
Class IIFDA: OngoingMidlab Incorporated
DrugDec 11, 2024
Rising Pharma Holding Duloxetine Delayed-Release Capsules USP, 30 mg, a) 30 count recall — FDA D-0106-2025
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit
Class IIFDA: OngoingRising Pharma Holding, Inc.
DrugDec 11, 2024
Aurobindo Pharma USA Cinacalcet Tablets, 90 mg recall — FDA D-0079-2025
cGMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limit
Class IIFDA: OngoingAurobindo Pharma USA Inc
DrugDec 11, 2024
Venofer (iron sucrose) Injection, USP 100 mg Elemental Iron per 5 mL (20 mg/mL), 5 mL recall — FDA D-0082-2025
Presence of Particulate Matter: Potential for glass delamination from the vials.
Class IIFDA: OngoingAmerican Regent, Inc.
DrugDec 11, 2024
Diltiazem Hydrochloride Extended-Release Capsules, USP 60 mg, Twice-a-Day Dosage recall — FDA D-0096-2025
cGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.
Class IIFDA: OngoingGlenmark Pharmaceuticals Inc., USA
DrugDec 11, 2024
Diltiazem Hydrochloride Extended-Release Capsules, USP 60 mg, Twice-a-Day Dosage recall — FDA D-0093-2025
cGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.
Class IIFDA: OngoingGlenmark Pharmaceuticals Inc., USA
DrugDec 11, 2024
Midlab Compliance Dishwashing Liquid & Antibacterial Soap, PCMX 0.1%, Net Contents: 1 recall — FDA D-0092-2025
cGMP Deviations: Out of specification results for micro in hand soap products.
Class IIFDA: OngoingMidlab Incorporated
DrugDec 11, 2024
Rising Pharma Holding Duloxetine DR Capsules USP 60 mg, a) 30 count (NDC 57237-019-30), b) recall — FDA D-0107-2025
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit
Class IIFDA: OngoingRising Pharma Holding, Inc.
DrugDec 11, 2024
Esomeprazole Magnesium for Delayed-Release Oral Suspension 40 mg, 30 Single-Dose Packets recall — FDA D-0102-2025
Labeling: Not Elsewhere Classified - Wrong NDC number
Class IIIFDA: OngoingZydus Pharmaceuticals (USA) Inc
How to use this monthly recall archive
Use this page to compare the recalls reported during the month, then open an individual record for the exact reason, classification, company, remedy or distribution information available from the official source. Monthly counts are descriptive, not a safety rating.